The National Medical Products Administration (NMPA) in China has granted approval to Eli Lilly & Co. (NYSE: LLY) for its Baqsimi (glucagon nasal powder spray), marking a significant advancement in the treatment of severe hypoglycemia in diabetic patients aged four and above. Hypoglycemia, a common and potentially dangerous complication of diabetes treatment, can be effectively managed with Baqsimi. The nasal powder spray offers a non-invasive and swift emergency treatment option, absorbed through the nasal mucosa without the need for inhalation, and can be administered within 30 seconds without specialized skills, boasting a success rate of up to 90%.
Baqsimi’s approval in China comes as a clinical trial waiver from the NMPA, supported by comprehensive global and real-world data. This glucagon nasal powder aerosol provides a rapid and effective increase in blood glucose levels in severe hypoglycemia cases, with a lower risk of subsequent hyperglycemia compared to glucagon injections, the traditional emergency treatment.- Flcube.com
